Basic Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Sep 15, 2022; 13(9): 752-764
Published online Sep 15, 2022. doi: 10.4239/wjd.v13.i9.752
Hyperglycemia and reduced adiposity of streptozotocin-induced diabetic mice are not alleviated by oral benzylamine supplementation
Christian Carpéné, Kristiyan Stiliyanov Atanasov, Francisco Les, Josep Mercader Barcelo
Christian Carpéné, Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR 1297, Toulouse 31432, France
Kristiyan Stiliyanov Atanasov, Josep Mercader Barcelo, Molecular Biology and One Health research group, Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, Palma 07122, Spain
Francisco Les, Department of Pharmacy, Faculty of Health Sciences, Universidad San Jorge, Villanueva de Gállego, Zaragoza 50830, Spain
Author contributions: Carpéné C designed the studies, isolated cells for in vitro experiments, reviewed the literature, designed the figures, wrote and revised the manuscript; Mercader Barceló J performed animal treatments, non-invasive and ex vivo explorations, Stiliyanov Atanasov K was involved in data mining, Les F contributed to statistical analysis, literature review and revised the manuscript.
Institutional review board statement: The study was approved by the I2MC Institutional Review Board: Institut des maladies métaboliques et cadiovasculaires (http://www.i2mc.inserm.fr/accueil).
Institutional animal care and use committee statement: Mice were housed and manipulated according to the INSERM guidelines and European Directive 2010/63/UE by competent and expert technicians or researchers in animal care facilities with agreement number A 31 555 011. The experimental protocol was approved by the local ethical committee CREFRE.
Conflict-of-interest statement: The authors declare no competing financial interests.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guideline.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Christian Carpéné, PhD, Senior Researcher, Institut des Maladies Métaboliques et Cardiovasculaires, INSERM UMR 1297, Université Paul Sabatier Toulouse III, CHU Rangueil, Bat L4, BP 84225, Toulouse 31432, France. christian.carpene@inserm.fr
Received: March 11, 2022
Peer-review started: March 11, 2022
First decision: April 25, 2022
Revised: May 13, 2022
Accepted: August 22, 2022
Article in press: August 22, 2022
Published online: September 15, 2022
Processing time: 181 Days and 22.2 Hours
Core Tip

Core Tip: In adipocytes, benzylamine (Bza) is oxidized by amine oxidases and stimulates glucose uptake. Bza oral administration alleviates insulin-resistant diabetes in obese and diabetic mice. It was investigated whether Bza was also antihyperglycemic in insulin-deficient type 1 diabetes. To this aim, a 0.5% Bza drinking solution was given to streptozotocin-induced diabetic mice. Oral Bza did not recover hyperglycemia and reduced adiposity of lipoatrophic and diabetic mice. A minimal level of adiposity was required to support benzylamine oxidation and to improve glucose utilization. Thus, the antidiabetic properties of Bza in obese and diabetic models, do not apply for diabetes with severe lipoatrophy.